{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.3","upperLimit":"70.4","value":"59.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Clinical benefit rate was defined as the percentage of participants who achieved a minimal response (MR) or better (including MR, PR, VGPR, CR, and sCR). MR was defined as per IMWG criteria as \\>=25% but less than or equal to (\\<=) 49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50% to 89%. In addition to the above criteria, if present at baseline, \\>=50% reduction in the size of soft tissue plasmacytomas was also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult participants aged 18 years or older, with multiple myeloma received the lymphodepleting chemotherapy (cyclophosphamide 300 milligrams per meter square \\[mg/m\\^2\\] intravenous \\[IV\\] infusion and fludarabine 30 mg/m\\^2 IV infusion daily, for 3 days \\[Day -7 to Day -5\\]). After 5 to 7 days of initiating lymphodepleting chemotherapy, participants received IV infusion of cilta-cel OOS at a total targeted dose of 0.75\\*10\\^6 chimeric antigen receptor (CAR)-positive viable T-cells/kg (dose range 0.5\\*10\\^6 CAR-positive viable T cells/kg to 1.0\\*10\\^6 CAR-positive viable T cells/kg) based on participant's body weight at apheresis or per exceptional release criteria determined alternative dose.","id":"OG000","title":"Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS)"}],"paramType":"NUMBER","populationDescription":"The all treated analysis set included all participants who received study intervention (cilta-cel OOS).","reportingStatus":"POSTED","timeFrame":"From Day 1 (post infusion) up to 18.6 months","title":"Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}